Tag Archives: biologics

Biologics to Play Leading Role in McKesson’s Strategy

McKesson Corporation announced a multi-year strategic growth initiative in 2018, focused on creating innovative new solutions that improve patient care delivery and drive incremental profit growth. The initiative comprises multiple growth pillars, and includes a comprehensive review of the company’s operations and cost structure, designed to increase efficiency, accelerate execution and improve long-term performance. McKesson’s […]

Amber Specialty Pharmacy Leads Patient Satisfaction

Amber Specialty Pharmacy leads patient satisfaction. Amber Pharmacy, a wholly owned subsidiary of Hy-Vee, is the No. 1 ranked specialty pharmacy in the U.S. for patient satisfaction with pharmacy employees, according to a recent Zitter Health Insights survey. The survey assessed numerous aspects of patient satisfaction and garnered responses from more than 3,000 patients across 38 […]

Top Healthcare Market Trends

Knowsource.com Announces Transition to Access Market Intelligence

  Many of the 2016 top healthcare market trends began back in 2012-to-2014, and finally emerged more clearly in 2015 for commercially insured populations. This year Access Market Intelligence identifies four (4) major themes emerging that creates the top trends to watch in 2016 into 2017. Themes encapsulating the Top Trends are Macro Issues Trending […]

Limited Distribution Networks

Limited Distribution Networks growth continues as Specialty Pharmacies compete to be chosen to distribute specialty pharmaceuticals. AMI’s report, Distribution Decision-Making for Specialty Drugs, found that Pharmaceutical manufacturers typically develop a product-specific distribution strategy dependent on company-specific criteria when bringing a new specialty drug to the market. Pharmaceutical manufacturers consider approximately 100-150 different specialty pharmacies (SPs) […]

Biosimilar Confusion and Insights

Since Virginia became the first state in May 2013 to enact legislation regulating a pharmacist’s substitution of an interchangeable biologic drug for a prescribed reference biologic drug, there has not been much activity or clarity on the issue. This issue continues to pit manufacturer versus manufacturer, and other stakeholders against each other in the policy […]

Genentech Distribution Decision

This is an example of a pharmaceutical company helping another group of healthcare stakeholders, health plans, because of an issue with health systems increasing cost of care. Stakeholders in the healthcare market, while working to reduce the cost of care, are trying to determine the best path to profitability. An example is Genentech’s decision to […]